WASHINGTON, Jan. 16 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the availability of a draft guidance for industry titled "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products."

This document provides recommendations on the appropriate use of these statistical methods to support primary inference in pivotal clinical trials designed to assess the effectiveness and safety of medical products.